SCHEMBL15516799

SCHEMBL15516799

Nc1ccc(Oc2ccnc(Cl)n2)c2cccnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
APAF1 O14727 1/20 0.44
TDP2 O95551 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MMP14 P50281 2/20 0.41
NSD2 O96028 1/20 0.39
CASP6 P55212 1/20 0.39
HSP90AA1 P07900 4/20 0.39
HSP90AB1 P08238 3/20 0.39
NR4A2 P43354 2/20 0.39
CCR1 P32246 1/20 0.39
CCR8 P51685 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6304611 0.84 IDO1 (0.45) G6PDMAPTNR4A2IDO1CYP3A4
SCHEMBL15518138 0.78 ALDH1A1 (0.58) MEN1KMT2AALDH1A1MAPTCASP6
SCHEMBL15485165 0.76 IMPDH2 (0.34) HTTMAP4K4GAA
SCHEMBL21593695 0.75 KDM4E (0.53) MEN1KMT2AALDH1A1MAPTAPAF1
SCHEMBL15484963 0.74 FEN1 (0.40) MAP4K4
SCHEMBL12695260 0.72 CYP1A2 (0.39) MEN1KMT2AALDH1A1MAPTCYP3A4
SCHEMBL625749 0.72 NSD2 (0.62) G6PDMEN1KMT2AALDH1A1MAPT
SCHEMBL19231173 0.71 KDM4E (0.51) MEN1KMT2AALDH1A1MAPTAPAF1
SCHEMBL28756211 0.71 PLAAT3 (0.39) MAPTKDM4ECYP3A4ALOX12TDP1
Hydrochloric Acid SCHEMBL20589073 0.71 NSD2 (0.60) G6PDMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796742-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-24 US disclosed
US-9732063-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-08-15 US disclosed
EP-2890460-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2017-02-22 EP disclosed
US-20160340375-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-11-24 US disclosed
EP-2925742-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2016-10-26 EP disclosed
US-20150329523-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2015-11-19 US disclosed
EP-2925742-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-10-07 EP disclosed
US-20150210722-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2015-07-30 US disclosed
EP-2890460-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-07-08 EP disclosed
WO-2014076484-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-05-22 WO disclosed
WO-2014033446-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210722-A1 KINASE INHIBITORS SYK, SRC, LYN G6PD 1649/4885MEN1 4580/4885KMT2A 2457/4885
US-20160340375-A1 KINASE INHIBITORS SYK, LYN, BTK G6PD 1539/4885MEN1 4489/4885KMT2A 2476/4885
US-20150329523-A1 KINASE INHIBITORS SYK, SRC, BTK G6PD 1354/4885MEN1 4570/4885KMT2A 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.